| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 41 | 2024 | 357 | 10.740 |
Why?
|
| Colitis, Ulcerative | 23 | 2024 | 261 | 6.580 |
Why?
|
| Crohn Disease | 23 | 2024 | 334 | 6.470 |
Why?
|
| Natural Language Processing | 7 | 2022 | 119 | 1.720 |
Why?
|
| Veterans | 10 | 2022 | 1743 | 1.680 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2018 | 459 | 1.510 |
Why?
|
| United States Department of Veterans Affairs | 11 | 2024 | 675 | 1.340 |
Why?
|
| Critical Pathways | 2 | 2019 | 160 | 1.110 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2024 | 18 | 1.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2023 | 1606 | 1.020 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2019 | 140 | 1.010 |
Why?
|
| Gastrointestinal Agents | 2 | 2017 | 119 | 0.990 |
Why?
|
| Gastroenterology | 5 | 2024 | 199 | 0.950 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 95 | 0.940 |
Why?
|
| Colitis | 2 | 2020 | 344 | 0.920 |
Why?
|
| Colonoscopy | 5 | 2022 | 522 | 0.880 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 362 | 0.870 |
Why?
|
| Quality Improvement | 4 | 2020 | 920 | 0.850 |
Why?
|
| Colorectal Neoplasms | 7 | 2022 | 3705 | 0.840 |
Why?
|
| United States | 31 | 2024 | 16018 | 0.820 |
Why?
|
| Biological Products | 3 | 2023 | 319 | 0.780 |
Why?
|
| Anxiety | 2 | 2020 | 1230 | 0.770 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 603 | 0.760 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 721 | 0.750 |
Why?
|
| Diet | 5 | 2019 | 1489 | 0.740 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 813 | 0.700 |
Why?
|
| Immunosuppressive Agents | 5 | 2022 | 1443 | 0.690 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2021 | 277 | 0.690 |
Why?
|
| Veterans Health | 5 | 2021 | 176 | 0.680 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2021 | 969 | 0.660 |
Why?
|
| Depression | 2 | 2020 | 1729 | 0.640 |
Why?
|
| Gastrointestinal Diseases | 2 | 2014 | 617 | 0.630 |
Why?
|
| Humans | 86 | 2024 | 271967 | 0.610 |
Why?
|
| Hematinics | 1 | 2019 | 109 | 0.600 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1046 | 0.590 |
Why?
|
| Age of Onset | 2 | 2016 | 856 | 0.580 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 113 | 0.570 |
Why?
|
| Gastric Acid | 1 | 2017 | 54 | 0.570 |
Why?
|
| Intestinal Mucosa | 6 | 2021 | 1125 | 0.560 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 59 | 0.560 |
Why?
|
| Virus Activation | 1 | 2018 | 236 | 0.540 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 225 | 0.540 |
Why?
|
| Tuberculin Test | 1 | 2017 | 136 | 0.530 |
Why?
|
| Middle Aged | 42 | 2024 | 90447 | 0.530 |
Why?
|
| Fissure in Ano | 1 | 2015 | 8 | 0.520 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 86 | 0.520 |
Why?
|
| Databases, Factual | 4 | 2018 | 2288 | 0.510 |
Why?
|
| Hepatitis B | 1 | 2018 | 274 | 0.500 |
Why?
|
| Proton Pump Inhibitors | 2 | 2018 | 273 | 0.500 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 130 | 0.500 |
Why?
|
| Male | 48 | 2024 | 129048 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 629 | 0.480 |
Why?
|
| Aged | 34 | 2024 | 73494 | 0.480 |
Why?
|
| Behavior Therapy | 1 | 2017 | 304 | 0.470 |
Why?
|
| Gastroenterologists | 2 | 2024 | 21 | 0.460 |
Why?
|
| Colon | 5 | 2021 | 691 | 0.460 |
Why?
|
| Cost of Illness | 1 | 2017 | 504 | 0.450 |
Why?
|
| Scedosporium | 1 | 2013 | 24 | 0.440 |
Why?
|
| Risk Factors | 17 | 2022 | 18028 | 0.440 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 643 | 0.440 |
Why?
|
| Diet Therapy | 1 | 2013 | 53 | 0.430 |
Why?
|
| Stress, Psychological | 2 | 2017 | 1039 | 0.430 |
Why?
|
| Safety-net Providers | 1 | 2013 | 55 | 0.430 |
Why?
|
| Female | 45 | 2024 | 149251 | 0.430 |
Why?
|
| Brain Abscess | 1 | 2013 | 69 | 0.420 |
Why?
|
| Frontal Lobe | 1 | 2013 | 170 | 0.420 |
Why?
|
| Adult | 34 | 2024 | 81964 | 0.420 |
Why?
|
| Infliximab | 3 | 2022 | 140 | 0.420 |
Why?
|
| Leukopenia | 1 | 2012 | 153 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 1233 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1433 | 0.400 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 1442 | 0.390 |
Why?
|
| Algorithms | 6 | 2022 | 3926 | 0.390 |
Why?
|
| Medical Audit | 1 | 2012 | 198 | 0.390 |
Why?
|
| Disease Management | 2 | 2017 | 1109 | 0.390 |
Why?
|
| Proctitis | 1 | 2011 | 19 | 0.380 |
Why?
|
| Lichen Planus, Oral | 1 | 2010 | 9 | 0.380 |
Why?
|
| Health Personnel | 1 | 2017 | 655 | 0.370 |
Why?
|
| Digestive System Neoplasms | 1 | 2011 | 79 | 0.370 |
Why?
|
| Barrett Esophagus | 4 | 2022 | 561 | 0.370 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 273 | 0.370 |
Why?
|
| Logistic Models | 6 | 2020 | 3462 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2022 | 9476 | 0.360 |
Why?
|
| Caregivers | 1 | 2017 | 745 | 0.360 |
Why?
|
| Prevalence | 5 | 2021 | 3417 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 566 | 0.350 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2010 | 68 | 0.350 |
Why?
|
| Androstadienes | 1 | 2010 | 172 | 0.340 |
Why?
|
| Endoscopy | 1 | 2013 | 501 | 0.340 |
Why?
|
| Mycoses | 1 | 2013 | 396 | 0.340 |
Why?
|
| Diarrhea | 1 | 2013 | 730 | 0.340 |
Why?
|
| Retrospective Studies | 18 | 2022 | 39817 | 0.320 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 402 | 0.320 |
Why?
|
| Radiation Injuries | 2 | 2020 | 1472 | 0.320 |
Why?
|
| Cryosurgery | 1 | 2011 | 196 | 0.320 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2020 | 372 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 2425 | 0.300 |
Why?
|
| Odds Ratio | 5 | 2020 | 2332 | 0.280 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 4503 | 0.280 |
Why?
|
| Young Adult | 12 | 2023 | 22167 | 0.270 |
Why?
|
| Program Evaluation | 3 | 2019 | 611 | 0.270 |
Why?
|
| Deglutition Disorders | 1 | 2010 | 489 | 0.270 |
Why?
|
| Immunologic Factors | 2 | 2023 | 669 | 0.260 |
Why?
|
| Quality of Life | 3 | 2022 | 4753 | 0.260 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4346 | 0.250 |
Why?
|
| Peptic Ulcer Perforation | 1 | 2005 | 18 | 0.250 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2005 | 36 | 0.250 |
Why?
|
| Fetus | 1 | 2009 | 675 | 0.250 |
Why?
|
| Drug Prescriptions | 3 | 2024 | 323 | 0.250 |
Why?
|
| Stomach Ulcer | 1 | 2005 | 109 | 0.240 |
Why?
|
| Bacteria | 2 | 2019 | 652 | 0.240 |
Why?
|
| Hospitalization | 3 | 2021 | 2187 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 613 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 559 | 0.230 |
Why?
|
| Incidence | 5 | 2021 | 5858 | 0.230 |
Why?
|
| Postoperative Complications | 2 | 2021 | 5695 | 0.230 |
Why?
|
| Medical Marijuana | 1 | 2024 | 25 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 5774 | 0.230 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 2 | 2021 | 23 | 0.220 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1177 | 0.220 |
Why?
|
| Prednisone | 2 | 2021 | 1036 | 0.220 |
Why?
|
| Oxadiazoles | 1 | 2023 | 60 | 0.220 |
Why?
|
| Age Factors | 5 | 2019 | 5516 | 0.220 |
Why?
|
| Electronic Health Records | 3 | 2017 | 972 | 0.220 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 107 | 0.220 |
Why?
|
| Needs Assessment | 1 | 2024 | 237 | 0.210 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 169 | 0.210 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2022 | 5 | 0.210 |
Why?
|
| Erythema Nodosum | 1 | 2022 | 15 | 0.200 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 249 | 0.200 |
Why?
|
| Uveitis | 1 | 2022 | 39 | 0.200 |
Why?
|
| Endoscopy, Digestive System | 2 | 2014 | 210 | 0.200 |
Why?
|
| Treatment Outcome | 7 | 2019 | 33911 | 0.190 |
Why?
|
| Adolescent | 8 | 2023 | 32743 | 0.190 |
Why?
|
| Calbindin 2 | 1 | 2021 | 43 | 0.190 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2022 | 131 | 0.190 |
Why?
|
| Budesonide | 1 | 2021 | 35 | 0.190 |
Why?
|
| Chronic Disease | 3 | 2021 | 1848 | 0.180 |
Why?
|
| Tissue Adhesions | 1 | 2021 | 51 | 0.180 |
Why?
|
| Arthritis | 1 | 2022 | 149 | 0.180 |
Why?
|
| Metronidazole | 1 | 2021 | 171 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 876 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 31062 | 0.180 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 5940 | 0.180 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 2348 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 1324 | 0.170 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 15264 | 0.170 |
Why?
|
| Adult Stem Cells | 1 | 2020 | 69 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4989 | 0.170 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2018 | 2 | 0.160 |
Why?
|
| Abdomen | 1 | 2021 | 348 | 0.160 |
Why?
|
| Colitis, Microscopic | 1 | 2018 | 16 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4819 | 0.160 |
Why?
|
| Texas | 4 | 2019 | 6435 | 0.150 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 224 | 0.150 |
Why?
|
| Time Factors | 5 | 2021 | 13129 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 221 | 0.150 |
Why?
|
| Gelsolin | 1 | 2017 | 17 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2024 | 844 | 0.150 |
Why?
|
| Actin Cytoskeleton | 1 | 2017 | 79 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 357 | 0.150 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 8 | 0.140 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 584 | 0.140 |
Why?
|
| Methotrexate | 2 | 2012 | 1033 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2021 | 527 | 0.140 |
Why?
|
| Ileum | 1 | 2017 | 175 | 0.140 |
Why?
|
| Adalimumab | 1 | 2017 | 47 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2021 | 599 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2021 | 623 | 0.140 |
Why?
|
| Biological Therapy | 1 | 2017 | 57 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2021 | 629 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2019 | 485 | 0.140 |
Why?
|
| Data Mining | 1 | 2017 | 86 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 1064 | 0.140 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 89 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 155 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2021 | 701 | 0.140 |
Why?
|
| Mass Screening | 2 | 2017 | 1547 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 5193 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 409 | 0.130 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 111 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2005 | 1050 | 0.130 |
Why?
|
| Focus Groups | 1 | 2017 | 286 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 303 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 311 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 257 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 224 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2014 | 6883 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 498 | 0.120 |
Why?
|
| Blood Cells | 1 | 2015 | 130 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 4496 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2017 | 494 | 0.120 |
Why?
|
| Alopecia | 1 | 2015 | 124 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 700 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2017 | 448 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 4655 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 1459 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 392 | 0.110 |
Why?
|
| Saliva | 1 | 2015 | 238 | 0.110 |
Why?
|
| Pneumonia | 1 | 2020 | 798 | 0.110 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2013 | 20 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 508 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 1434 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 1351 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 446 | 0.110 |
Why?
|
| Adenoma | 2 | 2016 | 744 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2018 | 6237 | 0.110 |
Why?
|
| Colostomy | 1 | 2013 | 80 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 847 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 941 | 0.110 |
Why?
|
| Neoplasm Staging | 4 | 2022 | 14003 | 0.110 |
Why?
|
| Ileostomy | 1 | 2013 | 47 | 0.110 |
Why?
|
| Azathioprine | 1 | 2012 | 74 | 0.110 |
Why?
|
| Phenotype | 3 | 2024 | 6515 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2015 | 221 | 0.100 |
Why?
|
| Smoking | 2 | 2024 | 2548 | 0.100 |
Why?
|
| Mercaptopurine | 1 | 2012 | 131 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 1099 | 0.100 |
Why?
|
| United Kingdom | 2 | 2024 | 289 | 0.100 |
Why?
|
| Esophagus | 1 | 2015 | 564 | 0.100 |
Why?
|
| Stem Cells | 1 | 2018 | 1235 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1263 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 20 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2012 | 739 | 0.090 |
Why?
|
| Fluticasone | 1 | 2010 | 22 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 96 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 1342 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 2322 | 0.090 |
Why?
|
| Meat | 1 | 2011 | 94 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2017 | 1891 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 13398 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2017 | 1941 | 0.090 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2010 | 21 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2011 | 126 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 128 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2013 | 321 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2012 | 355 | 0.090 |
Why?
|
| Biopsy | 4 | 2020 | 3543 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 919 | 0.090 |
Why?
|
| Sex Factors | 1 | 2015 | 2201 | 0.090 |
Why?
|
| Biomarkers | 2 | 2019 | 5098 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 240 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2014 | 681 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 177 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 2011 | 255 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 350 | 0.080 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 203 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 1055 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 302 | 0.080 |
Why?
|
| Esophagoscopy | 1 | 2010 | 310 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 649 | 0.080 |
Why?
|
| Radiography | 1 | 2013 | 1994 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 298 | 0.080 |
Why?
|
| Vegetables | 1 | 2011 | 330 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1729 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 916 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 3177 | 0.080 |
Why?
|
| Recurrence | 1 | 2017 | 4887 | 0.080 |
Why?
|
| Protective Factors | 2 | 2021 | 107 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 645 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2022 | 581 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2009 | 245 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2022 | 548 | 0.070 |
Why?
|
| Prognosis | 3 | 2017 | 22542 | 0.070 |
Why?
|
| Pregnancy | 2 | 2010 | 8110 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 262 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4391 | 0.070 |
Why?
|
| Thalidomide | 1 | 2009 | 595 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 681 | 0.060 |
Why?
|
| Cause of Death | 2 | 2021 | 785 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 88 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2011 | 2864 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6203 | 0.060 |
Why?
|
| Fractures, Bone | 2 | 2016 | 311 | 0.050 |
Why?
|
| Indans | 1 | 2023 | 71 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 156 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2024 | 495 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2010 | 1255 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 5995 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 5110 | 0.050 |
Why?
|
| Remission Induction | 1 | 2009 | 3645 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 387 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 3239 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2015 | 2908 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7794 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 123 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7925 | 0.050 |
Why?
|
| Urologic Surgical Procedures | 1 | 2021 | 94 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 386 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 29 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 163 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2020 | 387 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2017 | 12212 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Actinomyces | 1 | 2018 | 5 | 0.040 |
Why?
|
| Actinobacteria | 1 | 2018 | 14 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 367 | 0.040 |
Why?
|
| Bacillus | 1 | 2018 | 39 | 0.040 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 184 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 729 | 0.040 |
Why?
|
| Alarmins | 1 | 2017 | 9 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1243 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 157 | 0.040 |
Why?
|
| Child | 1 | 2019 | 30576 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2017 | 95 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 866 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2021 | 378 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 605 | 0.040 |
Why?
|
| Clone Cells | 1 | 2018 | 588 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1113 | 0.040 |
Why?
|
| Receptors, CXCR6 | 1 | 2016 | 16 | 0.040 |
Why?
|
| Sorting Nexins | 1 | 2016 | 17 | 0.040 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 23 | 0.040 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2016 | 30 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 7981 | 0.030 |
Why?
|
| Cell Separation | 1 | 2018 | 615 | 0.030 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2016 | 35 | 0.030 |
Why?
|
| Tenascin | 1 | 2016 | 56 | 0.030 |
Why?
|
| Adenylyl Cyclases | 1 | 2016 | 103 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 99 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 64 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 114 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2017 | 345 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 165 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 153 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2016 | 73 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 229 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8631 | 0.030 |
Why?
|
| Regional Medical Programs | 1 | 2015 | 21 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2018 | 702 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2015 | 77 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 689 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 120 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 617 | 0.030 |
Why?
|
| Mesalamine | 1 | 2015 | 8 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 83 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 55 | 0.030 |
Why?
|
| Software | 1 | 2022 | 1392 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 1718 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 164 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 398 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 369 | 0.030 |
Why?
|
| Leadership | 1 | 2016 | 263 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2020 | 1005 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 1397 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2422 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1283 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 502 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 420 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 3167 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 1325 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2014 | 522 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 123 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 1326 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2246 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3074 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 376 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 6904 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 423 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 1313 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 636 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2286 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 882 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 4983 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 1026 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 2534 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 736 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9317 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 5832 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4188 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 2138 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1953 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7300 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 4897 | 0.020 |
Why?
|
| Pain | 1 | 2014 | 1698 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7474 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 62782 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4200 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 36023 | 0.010 |
Why?
|